Skip to main content

Table 1 Baseline characteristics of hydroxychloroquine incident users by time period

From: Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines

 

Time period of initial prescription

 

Characteristics

2007–2008

2009–2010

2011–2012

2013–2014

2015–2016

All

(n = 3297)

(n = 4151)

(n = 4927)

(n = 4944)

(n = 3614)

(n = 20,933)

Sex (% female)

2617 (79)

3267 (79)

3822 (79)

3846 (78)

2751 (76)

16,303 (78)

Mean age, years (SD)

53.7 (15)

54.9 (15)

55.7 (15)

56.2 (15)

56.9 (15)

55.6 (15)

BMI, kg/m2 (mean +/− SD)

27.3 (6)

27.4 (6)

27.6 (6)

27.8 (6)

28.4 (6)

27.7 (6)

BMI category (%)

 Underweight (BMI < 18.5)

81 (3)

89 (2)

95 (2)

90 (2)

68 (2)

424 (2)

 Normal (BMI 18.5 – < 25)

1096 (37)

1371 (36)

1623 (36)

1553 (34)

1054 (31)

6697 (35)

 Overweight (BMI 25 – < 30)

942 (32)

1274 (34)

1530 (34)

1527 (34)

1139 (33)

6412 (33)

 Obese (BMI 30+)

815 (28)

1053 (28)

1271 (28)

1390 (31)

1157 (34)

5686 (30)

CKD (≥ stage 3)

213 (7)

344 (8)

366 (7)

366 (7)

283 (8)

1572 (8)

Tamoxifen use

26 (1)

47 (1)

66 (1)

69 (1)

54 (2)

262 (1)

Diabetes mellitus (%)

228 (7)

370 (9)

483 (10)

552 (11)

517 (14)

2150 (10)

Smoking status (% current smoker)

696 (22)

881 (22)

977 (20)

953 (20)

645 (18)

4152 (20)

Indication for HCQ (%)

 RA/inflammatory arthritis

1745 (53)

2352 (57)

2794 (57)

2863 (58)

2001 (56)

11,749 (56)

 SLE

459 (14)

462 (11)

481 (10)

415 (8)

283 (8)

2100 (10)

 Systemic autoimmune rheumatic diseasea

117 (4)

156 (4)

183 (4)

174 (4)

148 (4)

778 (4)

 Primary dermatologic disease

282 (9)

384 (9)

489 (10)

5142 (11)

486 (13)

2183 (10)

 All other indications

700 (21)

797 (19)

980 (20)

950 (19)

696 (19)

4123 (20)

  1. BMI body mass index, CKD chronic kidney disease, HCQ hydroxychloroquine, SLE systemic lupus erythematosus, RA rheumatoid arthritis
  2. aSystemic autoimmune rheumatic disease category excludes SLE and RA